Valvular & structural heart disease
Valve Academic Research Consortium High Bleeding Risk (VARC-HBR) criteria validation in transcatheter aortic valve implantation (TAVI) patients on oral anticoagulation
Authors' conclusion
The VARC-HBR criteria effectively identified distinct subgroups with a stepwise increase in major bleeding post-TAVI. However, their predictive performance for individual risk was moderate.
Study context
- Population
- TAVI patients on oral anticoagulation in the POPular PAUSE TAVI trialpatients included · moderate bleeding risk (≤1 minor criterion) 332 (39%) · high bleeding risk (1 major or 2 minor criteria) 337 (39%) · very high bleeding risk (≥2 major or ≥3 minor criteria) 187 (22%)
- Participants
- 856 patients
- Predictors
- VARC-HBR criteria
- Predicted outcome
- Major bleeding
Model performance
As reported in the abstract
up to 30 days after TAVI
AUC
Major bleeding
0.64(95% CI 0.58-0.70)
- Moderate discriminative performance
Further findings
Major bleeding by VARC-HBR risk category
- Major bleeding by VARC-HBR risk category: p<0.001
Calibration
- Good calibration with observed outcomes, despite higher-than-expected event rates
Original publication
VARC-HBR criteria validation in TAVI patients on oral anticoagulation. EuroIntervention. Published 15 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →